CBConstantin von Bibra

Constantin von Bibra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Constantin von Bibra has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Birgit Geertz

    Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf

    5 shared publications
  • Florian Weinberger

    Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf , Martinistrasse 52, 20246 Hamburg

    5 shared publications
  • Aya Shibamiya

    University Medical Center Hamburg-Eppendorf, 20246 Hamburg 1 Department of Experimental Pharmacology and Toxicology Germany

    4 shared publications
  • Maria Köhne

    University Medical Center Hamburg-Eppendorf, 20246 Hamburg 1 Department of Experimental Pharmacology and Toxicology Germany

    4 shared publications
  • Jutta Starbatty

    University Medical Center Hamburg-Eppendorf, 20246 Hamburg 1 Department of Experimental Pharmacology and Toxicology Germany

    3 shared publications
  • Thomas Eschenhagen

    University Medical Center Hamburg-Eppendorf, 20246 Hamburg 1 Department of Experimental Pharmacology and Toxicology Germany

    3 shared publications

Latest Publications

  • Open Access

    Impulse initiation in engrafted pluripotent stem cell-derived cardiomyocytes can stimulate the recipient heart

    by Tim Stüdemann, Barbora Schwarzova, Till Schneidewind, Birgit Geertz, Constantin von Bibra, Marie Nehring, Judith Rössinger, J. Simon Wiegert, Thomas Eschenhagen, Florian Weinberger

    Transplantation of pluripotent stem cell-derived cardiomyocytes is a novel promising cell-based therapeutic approach for patients with heart failure. However, engraftment arrhythmias are a predictable life-threatening complication and represent a major hurdle for clinical translation. Catheter-based electrophysiological analysis suggested that the ventricular arrhythmias were caused by an automaticity of the transplanted cells, but whether impulse generation by transplanted cardiomyocytes can propagate to the host myocardium and override the recipient rhythm has not been directly assessed experimentally. We used optogenetics to specifically activate engrafted cardiomyocytes, which resulted in impulse generation in the engrafted cardiomyocytes and stimulated the recipient heart (4/9 hearts). Thus, our study shows that transplanted cardiomyocytes can electrically couple to the host myocardium and stimulate the recipient heart, providing experimental evidence that cardiomyocyte automaticity can serve as a trigger for ventricular arrhythmias.

  • Open Access

    Immature human engineered heart tissues engraft in a guinea pig chronic injury model

    by Constantin von Bibra, Aya Shibamiya, Andrea Bähr, Birgit Geertz, Maria Köhne, Tim Stuedemann, Jutta Starbatty, Verena Horneffer-Van der Sluis, Ulrich C. Klostermeier, Nadja Hornaschewitz, et al.

    Engineered heart tissue (EHT) transplantation represents an innovative, regenerative approach for heart failure patients. Late preclinical trials are underway, and a first clinical trial started recently. Preceding studies revealed functional recovery after implantation of in vitro-matured EHT in the subacute stage, whereas transplantation in a chronic injury setting was less efficient. When transplanting matured EHTs, we noticed that cardiomyocytes undergo a dedifferentiation step before eventually forming structured grafts. Therefore, we wanted to evaluate whether immature EHT (EHTIm) patches can be used for transplantation. Chronic myocardial injury was induced in a guinea pig model. EHTIm (15×106 cells) were transplanted within hours after casting. Cryo-injury led to large transmural scars amounting to 26% of the left ventricle. Grafts remuscularized 9% of the scar area on average. Echocardiographic analysis showed some evidence of improvement of left-ventricular function after EHTIm transplantation. In a small translational proof-of-concept study, human scale EHTIm patches (4.5×108 cells) were epicardially implanted on healthy pig hearts (n=2). In summary, we provide evidence that transplantation of EHTIm patches, i.e. without precultivation, is feasible, with similar engraftment results to those obtained using matured EHT.


  • Open Access

    Immature human engineered heart tissues engraft in a guinea pig chronic injury model

    by Constantin von Bibra, Aya Shibamiya, Andrea Bähr, Birgit Geertz, Maria Köhne, Tim Stuedemann, Jutta Starbatty, Nadja Hornaschewitz, Xinghai Li, Eckhard Wolf, et al.

    A bstract: Engineered heart tissue (EHT) transplantation represents an innovative, regenerative approach for heart failure patients. Late preclinical trials are underway, and the first clinical trial has started in 2021. Preceding studies revealed functional recovery after implantation of in vitro-matured EHT in the subacute stage while transplantation in a chronic injury setting was less efficient. We hypothesized that the use of immature EHT patches (EHT Im ) could improve cardiomyocytes (CM) engraftment. Chronic myocardial injury was induced in a guinea pig model (n=14). EHT Im (15×10 6 cells) were transplanted directly after casting. Functional consequences were assessed by serial echocardiography. Animals were sacrificed four weeks after transplantation and hearts were excised for histological analysis. Cryo-injury lead to large transmural scars amounting to 26% of the left ventricle. Grafts were identified by a positive staining for human Ku80 and dystrophin, remuscularizing 9% of the scar area on average. The CM density in the graft was higher compared to previous studies with in vitro-matured EHTs and showed a greater population of immature CM. Echocardiographic analysis showed a small improvement of left ventricular function after EHT Im transplantation. In a small translational proof-of-concept study human scale EHT Im patches (4.5×10 8 cells) were epicardially implanted on healthy pig hearts (n=2). In summary, we provide evidence that transplantation of immature EHT patches without pre-cultivation results in better cell engraftment.


  • Open Access

    Contractile force of transplanted cardiomyocytes contributes to heart function after injury

    by Tim Stüdemann, Judith Rössinger, Christoph Manthey, Birgit Geertz, Rajiven Srikantharajah, Constantin von Bibra, Aya Shibamiya, Maria Köhne, Antonius Wiehler, J. Simon Wiegert, et al.

    Transplantation of pluripotent stem cell-derived cardiomyocytes represents an innovative therapeutic strategy for heart failure. Studies in small and large animals have demonstrated functional recovery of left ventricular function after cardiomyocyte transplantation 1–4 , and first clinical studies are currently underway 5 . Yet, the mechanism of action underlying graft-induced benefit is unknown 6 . Here we demonstrate that transplanted cardiomyocytes actively contribute to heart function. We transplanted cardiomyocytes with an optogenetic off-on switch in a guinea pig cardiac injury model. Light-induced inhibition of engrafted cardiomyocyte contractility resulted in a rapid decrease of left ventricular function that was fully reversible with the offset of photostimulation. Hence, our optogenetic approach demonstrated that transplanted cardiomyocytes actively participate in heart function, supporting the hypothesis that the delivery of new force-generating myocardium can serve as a regenerative therapeutic strategy.


  • Open Access

    Human engineered heart tissue transplantation in a guinea pig chronic injury model

    by Constantin von Bibra, Aya Shibamiya, Birgit Geertz, Eva Querdel, Maria Köhne, Tim Stuedemann, Jutta Starbatty, Arne Hansen, Bernhard Hiebl, Thomas Eschenhagen, et al.

    A bstract: Myocardial injury leads to an irreversible loss of cardiomyocytes (CM). The implantation of human engineered heart tissue (EHT) has become a promising regenerative approach. Previous studies exhibited beneficial, dose-dependent effects of human induced pluripotent stem cell (hiPSC)–derived EHT patch transplantation in a guinea pig model in the subacute phase of myocardial injury. Yet, advanced heart failure often results from a chronic remodeling process. Therefore, from a clinical standpoint it is worthwhile to explore the ability to repair the chronically injured heart. In this study human EHT patches were generated from hiPSC–derived CMs (15×10 6 cells) and implanted epicardially four weeks after injury in a guinea-pig cryo-injury model. Cardiac function was evaluated by echocardiography after a follow-up period of four weeks. Hearts revealed large transmural myocardial injuries amounting to 27% of the left ventricle. EHT recipient hearts demonstrated compact muscle islands of human origin in the scar region, as indicated by a positive staining for human Ku80 and dystrophin, remuscularizing 5% of the scar area. Echocardiographic analysis demonstrated no significant difference between animals that received EHT patches and animals in the control group (fractional area change 36% vs. 34%). Thus, EHT patches engrafted in the chronically injured heart but in contrast to the subacute model, grafts were smaller and EHT patch transplantation did not improve left ventricular function, highlighting the difficulties for a regenerative approach.